Statins slow the progression of advanced multiple sclerosis in clinical trial

March 18, 2014

Statins may provide doctors with an unlikely new weapon with which to slow the progression of multiple sclerosis (MS).

No treatments can currently abate the advanced stage of the disease, known as secondary progressive MS, which gradually causes patients to become more disabled.

In a two-year clinical trial involving 140 patients with secondary progressive MS, the drug simvastatin slowed brain shrinkage, which is thought to contribute to patients' impairments. Supporting this finding, patients on simvastatin achieved better scores on movement tests and questionnaires that assess disability than patients taking a placebo.

MS is a neurological condition that affects around 2.3 million people worldwide. Most patients are initially diagnosed with relapsing-remitting MS, which causes periodic attacks. Around 65 per cent of people with relapsing remitting MS develop secondary progressive MS within 15 years of being diagnosed. The secondary progressive phase is where MS has the most personal and societal costs.

The authors of the new study, which was led by Imperial College London, said the findings were very encouraging, but would need to be replicated in a larger trial. The work is published today in the Lancet.

"At the moment, we don't have anything that can stop patients from becoming more disabled once MS reaches the progressive phase," said Dr Richard Nicholas, co-author of the study from the Department of Medicine at Imperial. "Discovering that statins can help slow that deterioration is quite a surprise. This is a promising finding, particularly as statins are already cheap and widely used.

"We need to do a bigger study with more patients, possibly starting in the earlier phase of the disease, to fully establish how effective it is," he added.

Dr Nicholas ran the trial with Dr Jeremy Chataway, then in the Department of Medicine at Imperial and now at University College London.

Statins are taken by millions of people to lower cholesterol and prevent heart disease, but it's unclear why they would have a beneficial effect on MS.

Some small studies have found a small benefit from statins in relapsing remitting MS, which is more treatable.

Secondary progressive MS has proven more challenging to alleviate. In 2013, cannabis became the latest drug to prove unsuccessful at slowing the progression of MS in a clinical trial.

This clinical trial is the culmination of long-standing research led by Professor John Greenwood at the UCL Institute of Ophthalmology showing the potential therapeutic benefits of using to treat autoimmune diseases such as and uveitis.

Professor Greenwood said, "After nearly two decades of research, it is immensely gratifying to see this work progress into the clinic to deliver benefits to ."

Explore further: Researchers link body temperature to relapsing-remitting MS and fatigue

More information: J. Chataway et al, 'Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial', The Lancet 383 (2014), DOI: 10.1016/S0140-6736(13)62242-4

Related Stories

Researchers link body temperature to relapsing-remitting MS and fatigue

March 18, 2014
Kessler Foundation researchers have demonstrated for the first time ever that body temperature is elevated endogenously in relapsing-remitting multiple sclerosis (RRMS) and linked to worse fatigue. The article was published ...

New knowledge about treating multiple sclerosis

February 3, 2014
(Medical Xpress)—A study carried out at Victoria, and recently published online in the international scientific journal PLOS ONE, holds promise for patients suffering from secondary progressive MS, an advanced form of the ...

Some MS patients experience 'natural' improvements in disability

October 18, 2012
(Medical Xpress)—Multiple sclerosis (MS) patients sometimes experience "natural" improvements in disability at least over the short term, according to a new study led by researchers at the University of British Columbia ...

Cannabis constituent has no effect on MS progression, study shows

July 23, 2013
The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that ...

Antibody may be detectable in blood years before multiple sclerosis symptoms appear

February 21, 2014
An antibody found in the blood of people with multiple sclerosis (MS) may be present long before the onset of the disease and its symptoms, according to a study released today that will be presented at the American Academy ...

Recommended for you

Mechanism explains how seizures may lead to memory loss

October 16, 2017
Although it's been clear that seizures are linked to memory loss and other cognitive deficits in patients with Alzheimer's disease, how this happens has been puzzling. In a study published in the journal Nature Medicine, ...

Study shows people find well-being more so from special places than from mementoes

October 16, 2017
(Medical Xpress)—A team of researchers at the University of Surrey has found that people experience a feeling of well-being when thinking about or visiting a place that holds special meaning to them. They also found that ...

fMRI scans reveal why pain tolerance goes up during female orgasm and shows brain does not turn off

October 13, 2017
(Medical Xpress)—A team of researchers at Rutgers University has determined why women are able to tolerate more pain during the time leading up to and during orgasm. In their paper published in the Journal of Sexual Medicine, ...

Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer's disease

October 13, 2017
Microglia, immune cells that act as the central nervous system's damage sensors, have recently been implicated in Alzheimer's disease.

Restless legs syndrome study identifies 13 new genetic risk variants

October 13, 2017
A new study into the genetics underlying restless legs syndrome has identified 13 previously-unknown genetic risk variants, while helping inform potential new treatment options for the condition.

Blueberries may improve attention in children following double-blind trial

October 13, 2017
Primary school children could show better attention by consuming flavonoid-rich blueberries, following a study conducted by the University of Reading.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

alfie_null
not rated yet Mar 19, 2014
Some sense of how effective the therapy is would be helpful.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.